ATLANTA study

Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms (ATLANTA)

The ATLANTA Trial aims to investigate the role of treating the local prostate tumour and metastasis in men with newly diagnosed metastatic prostate cancer. Men with advanced prostate cancer that has spread well beyond the gland itself (metastatic) are currently treated with drug therapy alone, such as chemotherapy. However, there is growing evidence that some men may benefit from having their local prostate tumour treated, even though it has already spread. In addition, some men may benefit from having selected distant cancer deposits treated.  

ATLANTA will randomise men to two additional local treatment options Radical treatment (Surgery or Radiotherapy) OR Minimally Invasive Ablative Therapy (Prostate Cryotherapy or HIFU). In addition, some men in these treatment arms will receive specialised radiotherapy to cancer deposits, known as Stereotactic Ablative Radiotherapy (SABR).  All trial treatments will be in addition to the routine NHS standard of care treatment.

Men in the treatment arms will be compared to men who are undergoing routine NHS standard of care in the control arm. We will be primarily looking at whether these additional treatments delay the progression of the disease and secondly, whether overall survival is improved.